#United States #MedTech #financial results #Marlborough #Boston Scientific

Boston Scientific Reports Record Financial Performance for 2025

Boston Scientific Corporation has officially announced its financial results for the fourth quarter and overall performance for the year 2025, detailing impressive numbers that reflect significant gains in revenue and earnings. The company's net sales for Q4 reached an astounding $5.286 billion, representing a 15.9% increase from the previous year. This growth is particularly notable given that operational growth stood at 14.3%, with organic growth reflecting a robust 12.7% increase.

The reported net income for Boston Scientific shares attributed to common stockholders was $672 million, translating to an earnings per share (EPS) of $0.45, which is an increase from the $566 million or $0.38 EPS reported in the previous year. Adjusted EPS also saw an uptick to $0.80, compared to $0.70 a year prior, showcasing a strong operational performance.

In aggregate, for the year 2025, the company achieved total net sales of $20.074 billion, growing by 19.9%. This impressive growth consists of 19.2% on an operational basis and 15.8% organically. Notably, the net income attributable to Boston Scientific common stockholders amounted to $2.898 billion, or $1.94 per share, an increase from $1.853 billion or $1.25 per share recorded in the prior year. Adjusted EPS for the year stood at $3.06, a significant jump from $2.51 in 2024.

In a statement, CEO Mike Mahoney expressed his pride in the team's performance, saying, "2025 was another exceptional year for Boston Scientific, with our global teams delivering differentiated innovation and high performance that enabled us to exceed our goals. Our efforts have had a positive impact on millions of patient lives, and we are well poised for continued growth in the future."

Fourth Quarter Highlights

For Q4, the company exceeded its own guidance, particularly in sectors such as MedSurg and Cardiovascular, achieving net sales growth of 11.7% and 18.2% respectively from the previous year. The U.S. marked a net sales increase of 17.0%, while the Europe, Middle East, and Africa region (EMEA) followed with 12.4% growth and the Asia-Pacific region reported 15.2% net sales growth, highlighting the effective market penetration strategies adopted by the company.

Among significant developments during the fourth quarter, Boston Scientific also gained FDA approval for the FARAPOINT™ Pulsed Field Ablation (PFA) Catheter. This innovative device has the capability to create lesions in a focused manner, further solidifying the company’s position in advancing technologies for treating complex medical conditions.

Moreover, the launch of the SEISMIQ™ Intravascular Lithotripsy System and the initiation of key clinical trials, such as the OPTIMIZE trial which utilizes Cortex OPTIMAP™ Electrographic Flow (EGF) mapping technology, showcase Boston Scientific's commitment to enhancing healthcare outcomes through innovative solutions.

Financial Outlook for 2026

Looking ahead, Boston Scientific is optimistic about its growth trajectory, projecting net sales growth for 2026 to be approximately 10.5 to 11.5% on a reported basis and 10.0 to 11.0% on an organic basis. The anticipated adjusted EPS for the year is expected to be in the range of $3.43 to $3.49, reaffirming the company’s strong operational foundation.

In conclusion, Boston Scientific’s robust financial results for Q4 and the full year of 2025 not only highlight the company’s operational excellence but also underscore its commitment to innovation. The healthcare community and investors alike remain keenly interested in the company’s continued evolution as it sets the stage for future growth through advanced medical technologies.